Sarepta Stock Falls; Google Acquires Wiz for $32B

Sarepta Therapeutics reported the death of a patient due to acute liver failure after receiving its gene therapy, Elevidys, for Duchenne muscular dystrophy. This marks the first fatality linked to the therapy, though liver injury is a known risk associated with such treatments. The patient had a cytomegalovirus infection, which may have contributed to the severity of the liver damage. Following this news, Sarepta's stock plummeted, losing more than 25% of its value. Despite the incident, the company maintains that the benefit-risk profile of Elevidys remains positive and plans to update the drug's prescribing information. Additionally, Google announced a $32 billion acquisition of cybersecurity firm Wiz, marking its largest acquisition amid increased competition in the cloud computing sector.